Anti-Semaglutide (GLP-1 analog
ue) Antibody (SAA2594), 抗Semaglutide(GLP-1 analogue)抗体 (SAA2594)- 询价
- abinScience
- China
- HP899013
- 2026年03月03日
- ELISA
- Human
- Human
企业认证
相关产品推荐更多 >
Anti-Human PLAG1 Polyclonal Antibody, 抗人PLAG1多克隆抗体
￥2588
Anti-Human LGR4 Antibody (SAA0107), FITC, 抗人LGR4抗体 (SAA0107), FITC标记
询价
Research Grade Anti-Human CLDN18.2 (LB1904), 研究级Anti-Human CLDN18.2 (LB1904)
￥2588
Anti-Influenza A virus Neuraminidase/NA protein Antibody (SAA1424), 抗InfluenzaA virus Neuraminidase/NA protein抗体 (SAA1424)
￥1338
Anti-Human GATA3 Antibody (SAA0103), 抗人GATA3抗体 (SAA0103)
￥1338
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
\
- 亚型：
IgG1, kappa
- 形态：
Liquid
- 保存条件：
0.01M PBS pH 7.4
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Human
- 保质期：
1 year
- 抗原来源：
Human
- 目录编号：
HP899013
- 级别：
科研级别
- 库存：
999
- 供应商：
abinScience
- 宿主：
Human
- 应用范围：
ELISA
- 浓度：
1mg/ml
- 靶点：
Semaglutide, Ozempic, Rybelsus, Wegovy
- 抗体英文名：
Anti-Semaglutide (GLP-1 analogue) Antibody (SAA2594)
- 抗体名：
Anti-Semaglutide (GLP-1 analogue) Antibody (SAA2594)
- 规格：
50ug/100ug
| Product name | Anti-Semaglutide (GLP-1 analogue) Antibody (SAA2594) |
|---|---|
| Catalog No. | HP899013 |
| Host species | Human |
| Species reactivity | Human |
| Immunogen | \ |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Applications | ELISA |
| Target | Semaglutide, Ozempic, Rybelsus, Wegovy |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact with the lab for this information. |
| Accession | CAS: 910463-68-2 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Clone ID | SAA2594 |
| Note | For research use only |
abinScience, founded in 2023 in Strasbourg, France, is committed to developing and producing high-quality life science reagents. Rooted in one of Europe’s leading hubs for scientific innovation, abinScience empowers global research through reliable, efficient experimental solutions. Guided by the vision of “Empowering Bioscience Discovery,” we support scientists worldwide in advancing the frontiers of bioscience.
Technology and Innovation
Relying on the global leading position in antibody and protein research and more than 20 years of industry experience of its parent company ProteoGenix since 2003, abinScience has inherited advanced technologies and high-quality standards. In particular, the XtenCHO™ system developed by ProteoGenix, which has two modes of transient expression and stable expression, has been widely recognized as a core technology to improve the efficiency of protein production, providing a solid foundation for ab...
Product categories and application fields.
Main products.
10000+ high-activity proteins.
15000+ antibody series products:
Classic monoclonal antibody.
Monoclonal antibody
Internal control antibody, labeled antibody.
High-quality phosphorylation antibodies.
Highly specific nanobodies and small molecule antibodies.
Functional antibodies in vivo.
Low-background flow cytometry antibodies.
DNA/RNA antibodies and PEG antibodies.
1000+ reagent kit series products.
Large-scale packaging customization services: We offer personalized antibody design, protein production, molecular optimization, and experimental development services.
Application field
Infectious disease research: including viruses, superbugs, parasites, etc.
Neuroscience research: Supporting research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Immunology research: Covers the research needs of immune activation, inhibition, and allergies and abnormal reactions.
Oncology research: Supporting the development of tumor biology and anti-tumor drugs.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验• Semaglutide for the treatment of obesity. PMID: 34942372
• Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417
• Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703
• Wegovy (semaglutide): a new weight loss drug for chronic weight management. PMID: 34706925
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. PMID: 36578889
• Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. PMID: 38958939
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review. PMID: 38952487
• A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. PMID: 38629387
• Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. PMID: 28110911
三句话读懂一篇 CNS：颜宁团队 2023 首个研究成果发表；长期单身，患老年痴呆风险更高
）最有前途的干预手段之一，其机制不明。 2023 年 1 月 25 日，中国科学院过程工程研究所刘瑞田及于晓琳共同通讯在 Signal Transduction and Targeted Therapy 杂志发表研究论文 Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer's disease-like mouse model 的研究论文。 该研究表明抗 Aβ 抗体的 Fc
技术资料暂无技术资料 索取技术资料
